Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
RESEARCH TOOLSreports
Scinai Immunotherapeutics (SCNI) Stock Price & Analysis
299 Followers
SCNI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.23 - $15.50
Previous Close$4.06
Volume29.49M
Average Volume (3M)573.60K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)₪4.87M
Total Debt (Recent Filing)₪20.56M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Aug 22, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.76
Shares Outstanding464,293
10 Day Avg. Volume3,347,354
30 Day Avg. Volume573,604
Standard Deviation0.28
R-Squared0.22
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-0.37
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scinai Immunotherapeutics News
PremiumCompany Announcements
Scinai’s Psoriasis Treatment Shows Promising Results
PremiumCompany Announcements
Scinai Immunotherapeutics Advances with Promising Q1 ResultsPremiumCompany Announcements
Scinai Immunotherapeutics’ Key Shareholder Meeting
PremiumCompany Announcements
Scinai Immunotherapeutics Eyes Debt-Equity Swap
PremiumCompany Announcements
Scinai Immunotherapeutics Strives for Nasdaq Compliance
Ownership Overview
0.00%
Insiders
0.16% Mutual Funds
<0.01% Other Institutional Investors
99.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $2.23 and its highest was $15.50 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Currently, no data Available
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Aug 22, 2024 which is in 31 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Jul 02, 2024. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 838,578 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.361%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
---
Scinai Immunotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.79%
Trailing 12-Months
Company Description
Scinai Immunotherapeutics
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.
---
Technical Analysis
Adaptimmune Therapeutics
―
Eton Pharmaceuticals
―
Corvus Pharmaceuticals
―
Regeneron
―
---